Preclinical News and Research

RSS
Oncothyreon third quarter net income increases to $9.9 million

Oncothyreon third quarter net income increases to $9.9 million

University of Houston to enhance cancer research facilities

University of Houston to enhance cancer research facilities

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

New results from BioCryst's BCX4208 Phase 2b gout study

New results from BioCryst's BCX4208 Phase 2b gout study

High-field MRI can reveal tiny brain injuries in preterm infant

High-field MRI can reveal tiny brain injuries in preterm infant

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics first quarter GAAP net loss increases to $14.5M

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs

Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs

Daily intake of Souvenaid improves memory in people with mild AD

Daily intake of Souvenaid improves memory in people with mild AD

Acorda third quarter GAAP net income increases to $18.9 million

Acorda third quarter GAAP net income increases to $18.9 million

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex third quarter revenue increases to $1.3 million

Penn research group receives NCI grant to establish BETRNet

Penn research group receives NCI grant to establish BETRNet

Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma

Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD reports net income of $13.9 million for third quarter 2011

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Celldex third quarter net loss increases to $11.8 million

Celldex third quarter net loss increases to $11.8 million

Zalicus third quarter revenue increases to $2.4 million

Zalicus third quarter revenue increases to $2.4 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.